In a meta-analysis of randomized controlled trials, Pregabalin exhibited improved effectiveness in minimizing post-traumatic peripheral neuropathic pain (PTNP) and improving sleep interference when compared to the placebo group. Investigators sought to determine safety and effectiveness of Pregabalin versus placebo in PTNP. Google Scholar, PubMed, Web of Science, and Cochrane Library databases were searched for evidences.  For assessing the quality of randomized clinical trials (RCTs), the Cochrane tool was used.

Analysis of data was carried out using comprehensive meta-analysis software. The meta-analysis encompassed three RCTs with 821 participants. Pregabalin and placebo showed a statistically significant difference in terms of pain index (standardized mean difference [SMD] = -0.14) and sleep interference (mean difference [MD] = -0.25). Furthermore, there was a profound difference in somnolence (risk ratio [RR] = 2.78), dizziness (RR = 4.13), and concentration disturbance (RR: 2.97) between Pregabalin and placebo.

Pregabalin and the placebo group did not differ significantly in the following areas: headache (RR = 1.20), fatigue (RR = 1.42), nausea (RR = 1.52), constipation (RR = 1.84), and discontinuation (RR = 1.52). Pregabalin demonstrated greater effectiveness in mitigating PTNP and ameliorating sleep interference when compared to placebo. But, it was linked with adverse events. Additional RCTs are warranted for substantiating these findings.